Clinical Trial Update: A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002) [Phase 1]

View source ↗

Summary

Phase 1 study of Nemtabrutinib (MK-1026) in Japanese participants with mature B-cell neoplasms has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mature B-cell Neoplasms

Drugs mentioned

• Nemtabrutinib (nemtabrutinib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Mature B-cell Neoplasms | Phase 1 | Status: COMPLETED